Sarepta
Rare Disease Therapeutics · Cell & Gene Therapy

Sarepta revenue, results and funding

Sarepta filed revenue of $2.2B for 2025.

Data updated Nov 18, 2026 · Back to the company report
$2.2BRevenue, 2025
−$713.4MNet income, 2025

Results by year

YearRevenueNet incomeTotal assetsLANG_CR_S_M_TAX_PAIDLANG_CR_S_M_TAX_EXPENSELANG_CR_S_M_BUYBACKSLANG_CR_S_M_CAPEXLANG_CR_S_M_SBCLANG_CR_S_M_RNDLANG_CR_S_M_OPERATING_INCOMELANG_CR_S_M_CASHLANG_CR_S_M_DEBTLANG_CR_S_M_ACQUISITIONS
2025$2.2B−$713.4M$3.3B$37.6M$11.2M$25M$102M$123.4M$1.5B−$699.8M$801.3M$829M–
2024$1.9B$235.2M$4B$22.6M$25.5M$0$137M$184.3M$804.5M$218.1M$1.1B$1.1B–
2023$1.2B−$536M$3.3B$15.1M$15.9M$0$76.1M$182.5M$877.4M−$267.8M$428.4M$1.2B–
2022$933M−$703.5M$3.1B$1.7M$13.5M–$30.8M$233M$877.1M−$536.2M$966.8M$1.5B–
2021$701.9M−$418.8M$3.1B$583k−$168k–$38.5M$113.9M$771.2M−$459.7M$2.1B$563.7M–
2020$540.1M−$554.1M$3B$2.5M$1.1M–$82.2M$108.1M$722.3M−$564.2M$1.5B––
2019$380.8M−$715.1M$1.8B$933k$1.2M–$59.6M$78.6M$560.9M−$705.6M$835.1M–$172.6M
2018$301M−$361.9M$1.6B$1.5M−$692k–$61.2M$50.1M$401.8M−$343.6M$370.8M$420.6M–
2017$154.6M−$50.7M$1.3B$5.3M$2.1M–$12M$30.5M$166.7M−$171.6M$599.7M$431.1M–
2016$5.4M−$267.3M$424.1M–––$5.3M$30M$188.3M−$266.7M$122.4M$17.7M–
2015$1.3M−$220M$273.8M–––$3.4M$32.1M$146.4M−$220.2M$80.3M$26.8M–
2014$9.8M−$135.8M$295M–––$25.4M$20.3M$94.2M−$133.8M$73.6M$1.5M–
2013–−$112M$291.6M–––$2.4M$11.1M$72.9M−$90.3M$257M$1.6M–
2012–−$121.3M$205M–––$108k$3.1M$52.4M−$29.7M$187.7M$1.7M–
2011–−$2.3M$54.4M–––$1.2M$3.1M$66.9M−$35.9M$39.9M$1.8M–
Sources: SEC

How to cite

Sarepta, Financials. Alion, Nov 18, 2026. https://alion.io/company/sarepta/financials

.json · .md · CC BY-SA 4.0